Abstract: A diester of a fused ring compound of the formula (I): wherein: the fused rings are both aromatic; R1 and R4 to R6 substituents are H or ester moieties having C1 to C20 linear or branched alkyl chains; R2 and R3 are —C(O)OCxHy, wherein x is from 10 to 12 and y is from 21 to 25; two adjacent R1 to R4 substituents are —C(O)OCxHy, wherein x is from 10 to 12 and y is from 21 to 25; and when R3 and R4 are ester moieties, the alkyl chains of R4 are not C5 or C8; and polymer compositions containing the fused ring compound.

Abstract: The present invention relates to an optical adhesive film which has excellent adhesive strength at room temperature and has improved efficiency in a rework process since peel strength is low at high temperatures. When attaching a touchscreen panel and an LCD by using the adhesive film of the present invention and separating the touchscreen panel and the LCD at high temperatures, the touchscreen panel and the LCD can be separated from each other without causing damage thereto. Additionally, the optical film of the present invention comprises two adhesive layers, wherein peeling occurs at the first adhesive layer having an adhesive composition such that a peeling surface can be controlled according to the convenience of a user.

Abstract: Disclosed herein is a method for preparing large soluble graphenes. The method comprises attaching one or more hindering groups to the graphene, which can prevent face-to-face graphene stacking by reducing the effects of inter-graphene attraction. The large graphenes can absorb a wide spectrum of light from UV to near infrared, and are useful in photovoltaic devices and sensitizers in nanocrystalline solar cells.

Abstract: Disclosed herein are phenylindane dicarboxylic acid (PIDA) monomers, polymer compositions comprising the PIDA monomers, and methods of preparing PIDA monomers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Novel crystalline compounds with at least two aromatic moieties for use in the phase change inks. The crystalline compound is derived from bio-renewable materials and can be used in phase change ink compositions to impart desirable ink properties. For example, the crystalline compounds provide phase change ink compositions suitable for ink jet printing, including robust printing on coated paper substrates.

Abstract: Novel crystalline compounds with at least two aromatic moieties for use in the phase change inks. The crystalline compound is derived from bio-renewable materials and can be used in phase change ink compositions to impart desirable ink properties. For example, the crystalline compounds provide phase change ink compositions suitable for ink jet printing, including robust printing on coated paper substrates.

Abstract: A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C?O)R9, —(C?O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; R3 is hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R4 is hydrogen, alkyl, aryl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R5, R6, R7, and R8 are independently hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, alkoxyaryl or heterocyclic all either substituted or unsubstituted, or combine with each other, or R5 can combine with R4 to form a carbocyclic or heterocyclic ring; R9 and R10 are independently alkyl, alkoxy, aryl, naphthyl, styryl, alkenyl, cycloalkyl, alko

Abstract: The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula (I), pharmaceutical compositions having a compound of formula (I), and methods of treating or preventing cancer by administering an effective amount of a pharmaceutical composition having a compound of formula (I) to a subject in need thereof.

Abstract: An objective of the present invention is to provide a novel NDM (New Delhi metallo-?-lactamase) inhibitor that functions as a drug for restoring the antibacterial activity of ?-lactam antibiotics that have been inactivated as a result of decomposition by NDM.

Abstract: This invention relates to a method for making soluble precursors to imides, polyimides, and polymers containing imide groups, and a method of making thin films of the same by solution casting and then removing the solubilizing group to produce thermally stable and insoluble materials.

Abstract: Disclosed is a method for producing a liquid crystal polyester, which includes the steps of: (1) polycondensing a mixture of 70.5 to 71.5 mol % of a compound represented by the defined formula (I) (for example, 4-acetoxybenzoic acid) with 28.5 to 29.5 mol % of a compound represented by the defined formula (II) (for example, 6-acetoxy-2-naphthoic acid) to form a prepolymer, wherein the prepolymer has a flow initiation temperature of 200° C. or higher, and the mixture is polycondensed until reaching the temperature which is at least 30° C. lower than the polycondensation temperature; (2) removing the prepolymer in a molten state, followed by solidification and further grinding to produce prepolymer particles; and (3) subjecting the prepolymer particles to a heat treatment at 200 to 310° C. under circulation of an inert gas while remaining in a solid phase state.

Abstract: A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C?O)R9, —(C?O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; and R3-R9 are as described in the disclosure. Also featured are liquid crystal compositions comprising a chiral dopant compound represented by any of Structure 2-4 as described in the disclosure.

Abstract: Provided is a process for making non-phthalate plasticizers, by acylating an aromatic compound with a succinic anhydride to form a keto-acid, and then esterifying the keto-acid with C4-C13 OXO-alcohols to form a plasticizer compound. The aromatic rings of the aromatic compound may also be optionally hydrogenated.

Abstract: The present disclosure relates, according to some embodiments, to molecules, including conjugated fused polycyclic molecules, that may receive excited state energy from other molecules (e.g., light-absorbing molecules) or directly from the irradiation sources. According to some embodiments, the disclosure relates to molecules, including conjugated fused polycyclic molecules, that may resolve (e.g., quench, dissipate) excited state energy, normally by way of releasing it as heat. (e.g., as heat). Conjugated fused polycyclic molecules of various structures are disclosed including Formula III: The disclosure further relates to methods of use and/or therapy using molecules of Formulas I, II, and/or III.

Abstract: A crosslinkable curing super-branched polyester and the cured product and the preparation method thereof are disclosed. The super-branched polyester has high refractive index and comprises a compound represented by the following structural formula (I). In the formula (I), HBP is the backbone of the super-branched polyester; both a and b are positive integers; the sum of a and b is less than or equal to n; n is more than or equal to 10 and less than 80. In the super-branched polyester, A is represented by formula (II) and N is represented by formula (III), wherein R is methyl or hydrogen atom; the mole ratio of N relative to the total mole of A and N is more than 30 mol %, and the ratio of the total mole of A and N relative to the product of the total mole of HBP backbone and n is more than 0.5 and less than or equal to 1.

Abstract: A liquid crystal compound of Formula (I) is provided. In Formula (I), A is benzene, naphthalene, pyridine, furan, thiophene or a single bond, D is benzene, naphthalene, pyridine, furan, thiophene or a single bond, R1 and R2 are C1-10 alkyl, C1-10 alkoxy, fluoro or trifluoro methyl, E is benzene, naphthalene, pyridine, furan, thiophene or a single bond, W is —CO—O—, —O—CO—, —O—, —CH2—CH2—, —CH?CH—, —CH2—O— or a single bond, Z is benzene, naphthalene, pyridine, furan, thiophene or a single bond, Y is hydrogen, methyl, ethyl or propyl, m is 0, 1 or 2, p is 0, 1 or 2, r is 0, 1 or 2, q is 0, 1 or 2, and n is 0, 1, 2 or 3. The invention also provides a liquid crystal display and photochromic material including the compound.

Abstract: Naproxen-based ferroelectric liquid crystal (FLC) or nematic liquid crystal chiral compounds, which can be used in liquid crystal compositions useful for electro-optical and display device applications. The liquid crystal can be a ferroelectric liquid crystal. Also provided is a display device that includes the Naproxen-based ferroelectric liquid crystal (FLC) or nematic liquid crystal chiral compound. Also provided is a method of preparing a liquid crystal display device on silicon that includes incorporating the Naproxen-based ferroelectric liquid crystal (FLC) or nematic liquid crystal chiral compound, into a liquid crystal display on silicon by disposing the compound in a liquid crystal, or the liquid crystal, onto a silicon surface.

Abstract: An embodiment of the invention provides a chiral dopant having the following formula: wherein X1 and X2 are independently wherein F is fluorine, m is a positive integer from 1 to 8, and n is a positive integer from 1 to 4; Y1 and Y2 are independently —O—, —CH2CH2—, —CH?CH—, —C(O)O—, or —CH2O—; and R1, R2 are independently substituted or non-substituted C1-C10 linear alkyl, wherein substituents of the substituted C1-C10 linear alkyl are independently —F, —Cl, —OCF3, —NCS, or —CN, wherein a number of backbone carbon atoms in each of —Y1R1 and —Y2R2 is larger than 3.

Abstract: Disclosed is a method for reducing the appearance of a fine line or wrinkle on skin comprising topically applying to said fine line or wrinkle a composition comprising a glyceryl di-salicylate compound having the following structure: wherein the composition further includes a glyceryl mono-salicylate compound, and wherein the composition reduces the appearance of said fine line or wrinkle on skin.

Abstract: It is an object of the present invention to provide a new alcohol compound, a polyester resin, an unsaturated polyester resin, a resin particle and an electrophotographic toner using the compound capable of using the renewable resources as a part of a raw material. An alcohol compound according to the present invention is characterized by representing the chemical formula [Chemical 1]. Furthermore, the polyester resin or the unsaturated polyester resin according to the present invention, is characterized in that the compound (wherein X is an aliphatic or an aromatic residue, Y is a refined rosin residue, a disproportionated rosin residue or a hydrogenated rosin residue, and n=0 to 1 in the formula.) is an essential component of an alcohol component. Further, the resin particle of the present invention is characterized by comprising the polyester resin.

Abstract: Provided is a polymerizable compound with large solubility in a liquid crystal composition and high reactivity irradiated by ultraviolet in the longer wavelength range. Provided is a liquid crystal composition that satisfies at least one of characteristics such as high maximum temperature of a nematic phase, low minimum temperature of a nematic phase, small viscosity, suitable optical anisotropy, large negative dielectric anisotropy, large specific resistance, high stability to ultraviolet light and high stability to heat, or that is suitably balanced between at least two of the characteristics.

Abstract: Described herein are devices, compositions, and methods for improving color discernment.

Abstract: The invention relates to compounds of Formula (I): The invention further relates to liquid crystal compositions comprising compounds of Formula (I); compositions further comprising one or more chiral compounds; and polymer networks derived from the polymerization of the liquid crystal compositions. Another embodiment relates to processes for providing compounds of Formula (I).

Abstract: The invention relates to novel fluorene derivatives, which are especially suitable for use in birefringent films with negative optical dispersion, to novel liquid crystal (LC) formulations and polymer films comprising them, and to the use of the fluorene derivatives, formulations and films in optical, electrooptical, electronic, semiconducting or luminescent components or devices.

Abstract: A three-stage method for synthesizing 1,1-disubstituted olefins is provided.

Abstract: The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Abstract: Disclosed is a method for producing a liquid crystal polyester, which includes the steps of: (1) polycondensing a mixture of 70.5 to 71.5 mol % of a compound represented by the defined formula (I) (for example, 4-acetoxybenzoic acid) with 28.5 to 29.5 mol % of a compound represented by the defined formula (II) (for example, 6-acetoxy-2-naphthoic acid) to form a prepolymer, wherein the prepolymer has a flow initiation temperature of 200° C. or higher, and the mixture is polycondensed until reaching the temperature which is at least 30° C. lower than the polycondensation temperature; (2) removing the prepolymer in a molten state, followed by solidification and further grinding to produce prepolymer particles; and (3) subjecting the prepolymer particles to a heat treatment at 200 to 310° C. under circulation of an inert gas while remaining in a solid phase state.

Abstract: The present invention refers to new organic molecules, derived from the class of polycarbocycle derivatives, and their application as components of photoresists, and in particular as components of photoresist compositions where no polymer is comprised as one of the photoresists components. In these photoresist formulations the new molecule(s) is/are the main component(s) (i.e. percentage higher than 50% w/w).

Abstract: A polymerizable compound represented by general formula (1): wherein Z1 and Z2 each represent a (meth)acryloyloxy group; X1 and X2 each independently represent a single bond, an optionally branched alkylene group having 1 to 8 carbon atoms, an ether linkage, —COO—, —OCO—, —OCOO—, a 6-membered ring optionally having a substituent, or a combination thereof; R1 represents —R?, —OR?, —CO—R?, or —OCO—R?; R? represents a halogen atom, an optionally branched alkyl group having 1 to 8 carbon atoms, or a 6-membered ring optionally having a substituent, L1 and L2 each independently represent a member selected from a single bond, —CH2CH2—, —CH?CH—, —C?C—, —CH2O—, —OCH2—, —COO—, and —OCO—; m represents an integer of 1 to 4; and the R1's may be the same or different.

Abstract: The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the biologically active compound as such with no change in native chemical structure.

Abstract: Organic materials which possess outstanding stability to oxidative, thermal or light-induced degradation comprise as stabilizers at least one compound of the formula I wherein the general symbols are as defined in claim 1. The compounds of formula I are especially useful as stabilizers for protecting polymers and lubricants against oxidative, thermal or light-induced degradation and as scavengers for oxidized developer in color photographic material.

Abstract: An organic semiconductor material is provided. The organic semiconductor material includes a polyacene derivative expressed by the following general formula (1): where each of R1 to R10 may be independently the same substituents or different substituents but all of R1, R4, R5, R6, R9 and R10 may never be hydrogen atoms at the same time, and where each of R1 to R10 is at least one kind of substituent selected from the group consisting of an aliphatic hydrocarbon group having a substituent and of which number of carbon atoms ranges of from 1 to 20, an aromatic hydrocarbon group having a substituent, a complex aromatic group having a substituent, a carboxyl group, a hydride, an ester group, a cyano group, a hydroxyl group, a halogen atom and a hydrogen atom. The organic semiconductor material can be dissolved into an organic solvent at low temperature (for example, room temperature) and is suitable for use with a coating process.

Abstract: The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the biologically active compound as such with no change in native chemical structure.

Abstract: The purpose the invention is to provide a polymerizable liquid crystal compound which has an excellent solubility with other compounds, a high homeotropic property, and a spirobiindan-backbone, and a liquid crystal composition comprising this compound. The purpose is attained with a polymerizable liquid crystal compound represented by Formula (1). A polymer which is excellent in many characteristics can be obtained from this compound and a formed body having optical anisotropy, produced from this polymer can be obtained. In Formula (1), G is a single bond or oxygen; R is hydrogen, methyl (Me) or a group represented by Formula (a), wherein at least two of R are groups represented by Formula (a); P is a polymerizable group represented by any of Formula (P1) to Formula (P8). In Formula (a), a desirable A is 1,4-cyclohexylene or 1,4-phenylene; Z is a bonding group; m is an integer of 0 to 3; X0 is a single bond or alkylene; Z0 is a single bond, —O—, —OCO—, or —OCOO—; X is a single bond or alkylene.

Abstract: This invention relates to liquid crystal compositions, and polymer networks and articles comprising the compositions. The compositions comprise at least one compound of the group of compounds represented by the structures of each of the following Formulas (IV), (V) and (VI), as defined herein. A process for making the composition is also provided.

Abstract: Described herein are methods for treating inflammatory disorders or for inhibiting the build-up of arterial plaque. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.

Abstract: A liquid crystalline thermoset oligomer or polymer including a structural unit of Chemical Formulae 1 and 2; and a functional group of Chemical Formula A,

Abstract: Disclosed herein are methods of inhibiting the build-up of arterial plaque in a subject in need thereof. These methods comprise administering to the subject in need thereof a therapeutically effective amount of fullerenes.

Abstract: The compound of the present invention is represented by the formula (1). In the formula (1), R1 and R2 are hydrogen, fluorine, chlorine, methyl or ethyl; X1 and X2 are hydrogen, fluorine, methyl or trifluoromethyl; Z1 and Z2 are a single bond, —COO—, —OCO—, —CH?CH—COO—, —OCO—CH?CH—, —CH2CH2—COO—, —OCO—CH2CH2—, —CH2O—, —CONH—, —(CH2)4—, —CH2CH2— or —C?C—; Z3 and Z4 are a single bond or —O—; A1 and A2 are 1,4-cyclohexylene, 1,4-phenylene, 1,3-phenylene, pyridin-2,5-diyl, pyrimidin-2,5-diyl, naphthalen-2,6-diyl or tetrahydronaphtlane-2,6-diyl; and Y1 and Y2 are alkylene having from 2 to 20 carbon atoms.

Abstract: Described is the use of benzotropolone and their derivatives, especially the compounds of formula (1); wherein R2, R3, R4, R5 and R6 independently of one another are hydrogen; OH; C1-C30alkyl, C2-C30al-kenyl, C1-C30alkoxy, C3-C12cycloalkyl or C1C30hydroxyalkyl, which may be substituted by one or more E and/or interrupted by one or more D; C6-C20aryl, which may be substituted by one or more G; C4-C20heteroaryl, which may be substituted by one or more G, C2-C18alkenyl, C2-C18alkynyl, C7-C25aralkyl, CN, or —CO—R17; C1-C30mono- or dialkylamino; COR9; COOR9; CONR9R10; CN; SO2R9; OCOOR9; OCOR9; NHCOOR9; NR9COR10; NH2; *—(CO)—NH—(CH2)n1—(PO)—(OR11)2; —(CO)—O—(CH2)n1—(PO)—(OR11)2; sulphate; sulphonate; phosphate; phosphonate; —(CH2)n2—[O—(SO2)]n3—OR11; —O—(CH2)n4(CO)n5—R11; —(O)n6—(CH2)n7—(PO)—(OR9)2; —(O)n6—(CH2)n7—SO2—OR9; halogen; organosilanyl; organo-siloxanyl; or a sugar residue linked directly in an ?- or ?-mode via the anomeric oxygen to the benzotropolone system or via a linear or branched alkylene, alkenyle

Abstract: The invention relates to compounds of Formula (I): The invention further relates to liquid crystal compositions comprising compounds of Formula (I); compositions further comprising one or more chiral compounds; and polymer networks derived from the polymerization of the liquid crystal compositions. Another embodiment relates to processes for providing compounds of Formula (I).

Abstract: The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of ?-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions.

Abstract: The invention relates to compounds of Formula (I): The invention further relates to liquid crystal compositions comprising compounds of Formula (I); compositions further comprising one or more chiral compounds; and polymer networks derived from the polymerization of the liquid crystal compositions. Another embodiment relates to processes for providing compounds of Formula (I).

Abstract: It's object is to provide a (meth)acrylate compound excellent in photocurability, a curable composition comprising the compound and excellent in all of pattern accuracy, peelability, surface hardness, elasticity recovery and solvent resistance, an optical nanoimprint composition and a cured product of the curable composition and a method for producing it, especially to provide a composition favorable for a permanent film for flat panel displays, etc. A (meth)acrylate compound represented by the following formula (1): wherein R1 represents a hydrogen atom or a methyl group, R2 represents a substituent having carbon atoms of 2 to 6 and having a carbon-carbon double bond, X represents an organic group having carbon atoms of 1 to 10, m and n each are an integer of 1 to 3.

Abstract: The invention relates to novel fluorene derivatives, which are especially suitable for use in birefringent films with negative optical dispersion, to novel liquid crystal (LC) formulations and polymer films comprising them, and to the use of the fluorene derivatives, formulations and films in optical, electrooptical, electronic, semiconducting or luminescent components or devices.

Abstract: The present invention relates to 1,1?-bi-2-naphthol derivatives having (meth)acrylate groups, which can be used for preparing photocurable coating and has a refractive index of 1.53 or more. By using the present 1,1?-bi-2-naphthol derivatives, optical components with high refractive index and less light dispersion can be produced.

Abstract: The compound of the present invention is represented by the formula (1). In the formula (1), R1 and R2 are hydrogen, fluorine, chlorine, methyl or ethyl; X1 and X2 are hydrogen, fluorine, methyl or trifluoromethyl; Z1 and Z2 are a single bond, —COO—, —OCO—, —CH?CH—COO—, —OCO—CH?CH—, —CH2CH2—COO—, —OCO—CH2CH2—, —CH2O—, —CONH—, —(CH2)4—, —CH2CH2— or —C?C—; Z3 and Z4 are a single bond or —O—; A1 and A2 are 1,4-cyclohexylene, 1,4-phenylene, 1,3-phenylene, pyridin-2,5-diyl, pyrimidin-2,5-diyl, naphthalen-2,6-diyl or tetrahydronaphtlane-2,6-diyl; and Y1 and Y2 are alkylene having from 2 to 20 carbon atoms.

Abstract: A compound represented by the formula (I): wherein R1 represents a hydrogen atom etc., R2 and R3 each independently represent a hydrogen atom etc., R4 represents a C1-C8 divalent hydrocarbon group, R5 represents a single bond etc., and R6 represents an unsubstituted or substituted C6-C20 aromatic hydrocarbon group, a polymer comprising a structural unit derived from the compound represented by the formula (I) and a chemically amplified positive resist composition comprising the polymer, at least one acid generator and at least one solvent.

Abstract: Improved process for the continuous production of slow crystallizing polyester resin comprising esterification of at least one dicarboxylic acid or mono-esters thereof or di-esters thereof with at least one polyol, melt polymerizing the esterified mixture, preparing uniform crystalline hemispherical prepolymer by particle former process, adding at least one diol having tertiary or quaternary carbon atoms with pendant groups such as neopentyl glycol or 2-methyl-1,3-propanediol or any suitable diol at any stage during esterification or melt polymerization but before the particle former process; and solid state polymerizing the prepolymer to obtain high molecular weight slow crystallizing polyester. Slow crystallizing low molecular weight crystalline hemispherical prepolymer having IV of about 0.1 dl/g to about 0.45 and uniform hemispherical shape, uniform particle size, uniform crystallinity prepared by the above process and is used as precursor to prepare high molecular weight resin.

Abstract: The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.